<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119660</url>
  </required_header>
  <id_info>
    <org_study_id>BradleyH002</org_study_id>
    <nct_id>NCT05119660</nct_id>
  </id_info>
  <brief_title>Modulation of Frontoparietal Dynamics Underlying Adolescent Working Memory Deficits</brief_title>
  <official_title>Modulation of Frontoparietal Dynamics Underlying Adolescent Working Memory Deficits</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bradley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bradley Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether a single session of brain stimulation (called&#xD;
      repetitive transcranial magnetic stimulation [rTMS]) can improve the brain activity&#xD;
      underlying 'working memory.' Working memory is the ability to hold information 'in mind' to&#xD;
      complete daily activities. This study involves teenagers with ADHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Theta-Gamma Coupling After Sham iTBS</measure>
    <time_frame>Theta-gamma coupling will be obtained before and after iTBS administration. There will be approximately 5 minutes between the pre and post EEG recordings. The change between pre and post is the outcome variable.</time_frame>
    <description>EEG recording will be obtained while the participant completes the Sternberg Spatial Working Memory Test (SWMT). The coupling between theta phase and gamma amplitude will be extracted from the EEG during encoding and maintaining demands. The change between pre and post a single iTBS session will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Theta-Gamma Coupling after Active iTBS</measure>
    <time_frame>Theta-gamma coupling will be obtained before and after iTBS administration. There will be approximately 5 minutes between the pre and post EEG recordings. The change between pre and post is the outcome variable.</time_frame>
    <description>EEG recording will be obtained while the participant completes the Sternberg Spatial Working Memory Test (SWMT). The coupling between theta phase and gamma amplitude will be extracted from the EEG during encoding and maintaining demands. The change between pre and post a single iTBS session will be calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>Prefrontal cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, participants will receive stimulation to the left dorsolateral prefrontal cortex. They will complete one active session and one sham session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parietal cortex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, participants will receive stimulation to the left inferior parietal lobule. They will complete one active session and one sham session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intermittent Theta Burst Stimulation</intervention_name>
    <description>iTBS</description>
    <arm_group_label>Parietal cortex</arm_group_label>
    <arm_group_label>Prefrontal cortex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide assent and have parent provide parental permission&#xD;
&#xD;
          2. English fluency of the participant and the legal guardian/parent&#xD;
&#xD;
          3. 13-18 years&#xD;
&#xD;
          4. Parent rating on BRIEF-2 Working Memory: Greater than 1.0 SD above normative mean.&#xD;
&#xD;
          5. IQ &gt; 80&#xD;
&#xD;
          6. Clinical diagnosis of attention deficit hyperactivity disorder (ADHD): predominantly&#xD;
             inattentive type, predominantly hyperactive/impulsive type, combined type, or&#xD;
             unspecified type. Diagnostic criteria will be confirmed with NICHQ Vanderbilt&#xD;
             Assessment Scales-Parent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be screened to exclude individuals with neurological or medical&#xD;
        conditions that might confound the results, as well as to exclude participants in whom MRI&#xD;
        or TMS might result in increased risk of side effects or complications. Common&#xD;
        contraindications include metallic hardware in the body, cardiac pacemaker, patients with&#xD;
        an implanted medication pumps or an intracardiac line, or prescription of medications known&#xD;
        to lower seizure threshold. These account for the majority of the exclusion criteria listed&#xD;
        below:&#xD;
&#xD;
          1. Intracranial pathology from a known genetic disorder (e.g., NF1, tuberous sclerosis)&#xD;
             or from acquired neurologic disease (e.g. stroke, tumor), cerebral palsy, history of&#xD;
             severe head injury, or significant dysmorphology&#xD;
&#xD;
          2. History of fainting spells of unknown or undetermined etiology that might constitute&#xD;
             seizures&#xD;
&#xD;
          3. History of seizures, diagnosis of epilepsy, or immediate (1st degree relative) family&#xD;
             history epilepsy&#xD;
&#xD;
          4. Any progressive (e.g., neurodegenerative) neurological disorder&#xD;
&#xD;
          5. Chronic (particularly) uncontrolled medical conditions that may cause a medical&#xD;
             emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia,&#xD;
             asthma, etc.)&#xD;
&#xD;
          6. Contraindicated metal implants in the head, brain or spinal cord (excluding dental&#xD;
             implants, braces or fillings)&#xD;
&#xD;
          7. Non-removable makeup or piercings&#xD;
&#xD;
          8. Pacemaker&#xD;
&#xD;
          9. Implanted medication pump&#xD;
&#xD;
         10. Vagal nerve stimulator&#xD;
&#xD;
         11. Deep brain stimulator&#xD;
&#xD;
         12. TENS unit (unless removed completely for the study)&#xD;
&#xD;
         13. Ventriculo-peritoneal shunt&#xD;
&#xD;
         14. Signs of increased intracranial pressure&#xD;
&#xD;
         15. Intracranial lesion (including incidental finding on MRI)&#xD;
&#xD;
         16. History of head injury resulting in prolonged loss of consciousness&#xD;
&#xD;
         17. Substance abuse or dependence within past six months (i.e., DSM-5 substance use&#xD;
             disorder criteria)&#xD;
&#xD;
         18. Chronic treatment with prescription medications that decrease cortical seizure&#xD;
             threshold, not including psychostimulant medication if deemed to be medically safe as&#xD;
             part of the medical review process.&#xD;
&#xD;
         19. Active psychosis or mania&#xD;
&#xD;
         20. Current suicidal intent&#xD;
&#xD;
         21. Current pregnancy&#xD;
&#xD;
         22. Significant visual, hearing or speech impairment&#xD;
&#xD;
         23. Current wards of the state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>E. P. Bradley Hospital</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

